Business, energy, technology, markets and global industry news from Business News Today

adjunctive therapy

PharmaDeviceNews adjunctive therapy
Representative image showing neuroscience-based psychiatric treatment research as Evecxia Therapeutics builds the case for EVX-101 as a potential adjunctive therapy for patients with depression, obsessive-compulsive disorder and inadequate SSRI response.
Pharma & Biotech

Can Evecxia Therapeutics turn EVX-101 into the first serotonin synthesis amplification therapy?

EVX-101 revives serotonin synthesis as an SSRI add-on strategy. Can Evecxia prove old biology still has new clinical value?

Read More
Representative image of pharmaceutical tablets and clinical tools, reflecting ongoing advancements in adjunctive therapies like CAPLYTA (lumateperone) for major depressive disorder.
Pharma & Biotech

Can J&J’s lumateperone raise the bar for MDD remission? New CAPLYTA data fuels fresh hope

Johnson & Johnson (J&J) has presented new pooled data from Phase 3 clinical trials showing that CAPLYTA (lumateperone), used as an adjunctive therapy with antidepressants, significantly improved remission rates in adults with major depressive disorder compared to placebo. The results, highlighted at the 64th Annual Meeting of the American College of Neuropsychopharmacology, indicate nearly double

Read More